Home > Haematology > EHA 2022 > DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in patients with high-risk Burkitt lymphoma

DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in patients with high-risk Burkitt lymphoma

Presented By
Prof. Martine Chamuleau, Amsterdam UMC, the Netherlands
Conference
EHA 2022
Results from the prematurely closed HOVON/SAKK trial demonstrate equal efficacy of DA-EPOCH-R and CODOX-M/R-IVAX regimen as first-line treatment in patients with high-risk Burkitt lymphoma. However, DA-EPOCH-R is less toxic. Burkitt lymphoma is a (outside of Africa) rare but aggressive form of non-Hodgkin B-cell lymphoma for which the optimal first-line treatment remains to be defined. Treatment with high-dose multi-agent chemotherapy such as R-CODOX-M/R-IVAC is effective (2-year progression-free survival [PFS] of 64–71%), however at the cost of significant toxicity and long hospitalisation [1]. Treatment with lower intensity, patient dose-adjusted, and continuous DA-EPOCH-R has demonstrated favourable 2-year PFS of 85% and lower toxicity [2]. The multicentre, randomised HOVON/SAKK trial (EudraCT2013-004394-27) compared both reg...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on